New Phase 3 Parkinson's drug candidate
Meet the scientific leaders who are changing medicine
以下正文同步自 Hacker News 最新,版权归原站所有,已转换为易读排版。
Skip to main content
The rockefeller university
Search Input
Search Submit Button
Our Scientists
Overview
Heads of Laboratories
Tri-Institutional & Adjunct Faculty
Research Affiliates
Postdoctoral Researchers
Independent Fellows
Emeritus Faculty
Faculty Recruitment
Meet the scientific leaders who are changing medicine
Research
Overview
Research Areas and Laboratories
Interdisciplinary Centers
Clinical Research Center
Scientific Publications
Technology Transfer
Scientific Resource Centers
Translational Research
Research Policies
Peek inside our 72 biomedical laboratories
Education & Training
Overview
Graduate Program in Bioscience
Clinical Scholars Program
Chemers Neustein Summer Undergraduate Research Fellowship Program (SURF)
RockEDU Science Outreach
Career Development
Learn more about our flexible, supportive academic programs
News
News & Highlights
Philanthropy News
Campus News
Seek Magazine
Rockefeller University Press
For the Press
Rockefeller Publications
Learn about the breakthroughs happening every day
Events & Lectures
Upcoming Events
Calendar of Events & Lectures
Academic Lectures & Symposia
Special Events
Facility Rental
Hear from the world’s leading speakers and thinkers
About
Overview
Awards & Honors
Office of University Life and Community Engagement
Campus & Community
Executive Leadership
Our History
Our Impact
Board of Trustees & Corporate Officers
We’ve spent 125 years perfecting the bioscience institute
Support Our Science
Overview
Discover 125
Philanthropy News
Why Rockefeller is Unique
Rockefeller University Council
Women & Science
Ways to Support Rockefeller
Planned Giving
Campaign for the Convergence of Science and Medicine
Make a Gift
Shape the future of biology and medicine
Calendar
Directory
Careers
Give
Search Toggle Button
Search Toggle Button
Search
Submit
News & Highlights
Science News
New Parkinson’s drug candidate has roots in a Rockefeller lab
October 23, 2026
SHARE
COPY LINK
link copied to clipboard
A medium spiny neuron, with GPR6, the target of the new drug Solengpras, fluorescing in red. (Credit: Heintz lab)
Earlier this month, the biotech company Cerevance announced that its experimental Parkinson’s drug, solengepras, had succeeded in a large phase 3 clinical trial. Adding a once-daily solengepras pill to their usual medication regimen gave people with Parkinson’s more time each day with their symptoms under control, improved their ability to manage everyday activities, and eased their daytime sleepiness.
“For some patients, this drug completely changed their life,” says Nathaniel Heintz, head of the Laboratory of Molecular Biology at Rockefeller. “It’s not just they move better; they feel better.”
For Heintz—who identified the drug target behind solengepras nearly two decades ago—the new results are a success story because of how much they help patients. But they also offer some of the first real validation that drugs aimed at a single, precisely defined circuit in the brain can work to treat disease in people, an idea that Heintz has built his career around.
Most neurological drugs that make it through late-stage trials act on a target that other medicines already hit. Solengepras works on a molecule that almost no one had studied until Heintz’s lab flagged it in 2008 while studying precise differences between different brain cell types in the lab.
“This is a brand-new target, a brand-new drug,” says Brad Margus, the current chair of Cerevance’s board who co-founded the company with Heintz and served as its CEO until 2022.
And solengepras may be just the beginning. The same tools Heintz developed to uncover its target have already revealed several other molecules unique to specific brain cells. Some of them are already being pursued as potential treatments for Alzheimer’s disease, addiction, and other conditions.
“I think this opens up a lot of potential for new targets,” says Heintz, who also directs Rockefeller’s Fisher Center for Alzheimer’s Disease Research.
The missing data on different brain cells
In the late 1990s, Heintz was a molecular biologist studying cancer biology and specifically how cells divide, with no formal training in neuroscience. But he became captivated by a basic question about the brain, which contains hundreds of types of neurons and supporting cells.
“What was unknown at the time was how the different neurons and glia in the nervous system differed from one another at a molecular level, and I thought we could approach that,” he says. “What is so great about working at Rockefeller is that I got full support to completely shift the focus of my research. That’s rare in academia. I don’t think I would have been able to accomplish what I have anywhere else.”
Indeed, Heintz’s entire lab pivoted to work on the problem of how to define all the cell types in the brain. First, they developed a new way to genetically engineer mice so that certain of these cell types glowed under a microscope. That let them sort out the different types and—using another new technology devised by the lab—determine exactly which genes each was actively using.
By comparing these profiles—not only between cell types but between healthy and diseased brains—Heintz suspected he would be able to find new, highly precise drug targets. A drug that acts on a molecule found in only one cell type, he reasoned, would avoid many of the side effects common in existing neurological drugs, which often impact multiple cell types and brain regions at once.
正文由 探How 从来源站点 RSS 同步,内容未经改写;遇到排版缺失或需要图片、视频时请以原文为准。